Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus Dasatinib in ARID1A-mutated NSCLC
NCT04284202Phase 2Unknown
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Mar 2020
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors, Fragment-Derived Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, dasatinib in non-small cell lung cancer (NSCLC), sponsored by The Affiliated Hospital of Qingdao University. Status: unknown.
02
Drugs
toripalimabdasatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04284202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04284202.